- Stocks
- Pharma & Healthcare
- Espire Hospital
Espire Hospital share price
NSE: ESPIREPharma & HealthcareResorts & Casinos
Espire Hospital at a glance
With a market capitalisation of ₹274 Cr, it ranks 2105th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Resorts & Casinos.
Its return on equity was 19.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹43 Cr (+5.0% year on year) and net profit ₹4 Cr (−6.0%), on a standalone basis. Promoters held 69.25% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹274 CrRank 2105 on NSE
- Price to book
- 15.5×FY25
- EPS (TTM)
- ₹6.14to Q4 FY26
- ROE
- 19.0%FY25
- ROCE
- 11.6%FY25
- Debt to equity
- 1.68FY25
- Net profit margin
- 6.9%FY25
- Book value / share
- ₹29.15FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Espire Hospital quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹17 Cr | ₹20 Cr | ₹41 Cr | ₹41 Cr | ₹32 Cr | ₹19 Cr | ₹41 Cr | ₹43 Cr |
| Revenue YoY | +74.3% | +317.7% | +259.4% | +310.8% | +90.7% | −6.9% | −0.5% | +5.0% |
| Net profit | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹4 Cr | ₹1 Cr | −₹6 Cr | ₹8 Cr | ₹4 Cr |
| Net profit YoY | −95.7% | +380.0% | +213.5% | +483.1% | +4,666.7% | −694.8% | +193.5% | −6.0% |
| Net margin | 0.2% | 4.7% | 6.8% | 11.1% | 4.5% | −30.2% | 20.0% | 9.9% |
| EPS | ₹0.02 | ₹0.71 | ₹2.07 | ₹3.26 | ₹1.04 | −₹3.81 | ₹6.07 | ₹2.84 |
Espire Hospital financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹19 Cr | ₹36 Cr | ₹120 Cr |
| Operating profit | −₹0 Cr | −₹1 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹11 Cr |
| Net profit | −₹0 Cr | −₹1 Cr | −₹0 Cr | ₹0 Cr | ₹3 Cr | ₹8 Cr |
| EPS (₹) | −₹0.07 | −₹0.49 | −₹0.06 | ₹0.16 | ₹1.90 | ₹6.05 |
| Cash from operations | −₹0 Cr | ₹0 Cr | ₹4 Cr | ₹6 Cr | ₹3 Cr | −₹23 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹9 Cr | ₹46 Cr | ₹70 Cr |
| Shareholders' equity | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹44 Cr |
Espire Hospital shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.25% | 69.25% | 69.25% | 69.25% | 69.25% | 69.25% |
| Foreign institutions | 2.08% | 2.08% | 2.08% | 2.08% | 2.08% | 2.08% |
| Non-institutions | 28.67% | 28.67% | 28.67% | 28.67% | 28.67% | 28.67% |
Espire Hospital vs peers
The listed Pharma & Healthcare companies nearest to Espire Hospital by market capitalisation.
Ask anything about Espire Hospital
Pivot answers on the live chart with evidence you can check, and tests strategies against ESPIRE's own history. Try: “Why has ESPIRE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ESPIRE over five years” · “Compare ESPIRE with ASTONEALAB on margins and valuation”
Frequently asked questions about Espire Hospital
What is the market cap of Espire Hospital?
Espire Hospital's market capitalisation is ₹274 Cr (₹274 Cr) at the 22 Oct 2026 close, ranking 2105th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Espire Hospital?
Return on equity was 19.0% in FY25 and return on capital employed was 11.6% in FY25 (standalone figures).
Is Espire Hospital a debt-free company?
No. Espire Hospital's debt-to-equity ratio was 1.68 in FY25, with total debt of ₹70 Cr.
What were Espire Hospital's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Espire Hospital reported revenue of ₹43 Cr, +5.0% year on year, and net profit of ₹4 Cr, −6.0% year on year.
What is the shareholding pattern of Espire Hospital?
As of 30 Jun 2026: promoters 69.25%, foreign institutions 2.08%, non-institutions 28.67%.
Who are Espire Hospital's competitors?
The listed Pharma & Healthcare companies closest to Espire Hospital by market cap are Astonea Labs, Ambalal Sarabhai Enterprises, Zenotech Labs, Everest Organic, Gennex Labs and Kerala Ayur.
Is Espire Hospital a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Espire Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ESPIRE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text